Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer
Move Follows NICE Recommendation For England In July
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
You may also be interested in...
AstraZeneca and MSD's Lynparza can now be paid for through England’s Cancer Drugs Fund for use in women with advanced BRCA-mutated ovarian cancer when their disease is newly diagnosed and when the drug may have the potential to cure their disease.
Transparency on COVID-19 vaccine funding, pricing and procurement is vital if vaccine hesitancy and disinformation are to be countered, say EU parliamentarians.
Coronavirus Notebook: EU & Australia Assessing Comirnaty In 5-11 Year Olds, Aviptadil shows Promise In Critical COVID-19 Patients
The European Medicines Agency has OKd new manufacturing sites and a ready-to-use formulation for Comirnaty, while Australia has provisionally approved Ronapreve for treatment and post-exposure prophylaxis. The UK has secured supplies of two investigational antiviral products from Pfizer and MSD.